Evolv Technologies 株価情報 (NASDAQ: EVLV)

Evolv Technologies (NASDAQ:EVLV) 株価情報

Evolv Technologies

Evolv Technologies Holdings Inc offers an AI-based touchless security screening. Its touchless security screening systems use artificial intelligence software, cloud services, and advanced sensors to reliably detect dangerous weapons while ignoring harmless items like cell phones, laptops, and keys. It offers products for purchase and primarily under a multi-year security-as-a-service subscription pricing model that delivers ongoing value to customers, generates predictable revenue, and creates expansion and upsell opportunities. The firm operates in a single segment that develops, manufactures, markets, and sells security screening products and specific services. Its products are used in different industries such as casinos, industrial workplaces, schools, and ticketed venues.

Evolv Technologies Holdings, Inc. - Class A Common Stock

Evolv Technologies Holdings Inc

Evolv Technologies Holdings, Inc. - Warrant

The most oversold stocks in the information technology sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the<a href="https://www.benzinga.com/topic/rsi"> RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">ASGN Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASGN#NYSE">ASGN</a>)</h3>
<ul>
<li>On April 23, ASGN reported a first-quarter adjusted EPS miss and issued second-quarter EPS and adjusted EPS guidance below estimates. &#8220;ASGN entered the first quarter of 2025 with a continued focus on supporting our clients&#8217; long-term IT roadmaps. Despite macro uncertainty, our revenues and adjusted EBITDA results were in line with our guidance expectations,&#8221; said ASGN&#8217;s Chief Executive Officer, Ted Hanson. The company's stock fell around 19% over the past month and has a 52-week low of $47.64.</li>
<li>RSI Value: 29</li>
<li>ASGN Price Action: Shares of ASGN fell 0.4% to close at $50.86 on Tuesday.</li>
<li>Edge Stock Ratings: 10.42 Momentum score with Value at 41.67. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/ASGN"><img loading="lazy" decoding="async" width="487" height="181" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30041001/image-224.png" alt="" class="wp-image-894295" style="width:363px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30041001/image-224.png 487w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30041001/image-224-300x111.png 300w" sizes="(max-width: 487px) 100vw, 487px" /></a></figure>
<h3 class="wp-block-heading">Hackett Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCKT#NASDAQ">HCKT</a>)    </h3>
<ul>
<li>On April 29, Barrington Research analyst Vincent Colicchio maintained Hackett Group with an Outperform rating and maintained a $36 price target. The company's stock fell around 12% over the past month and <a href="https://www.benzinga.com/quote/HCKT">has a 52-week low</a> of $20.23.</li>
<li>RSI Value: 27.1</li>
<li>HCKT Price Action: Shares of Hackett gained 1.7% to close at $25.77 on Tuesday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0430">HCKT stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0430"><img loading="lazy" decoding="async" width="916" height="846" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30041114/image-225.png" alt="" class="wp-image-894296" style="width:579px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30041114/image-225.png 916w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30041114/image-225-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30041114/image-225-768x709.png 768w" sizes="(max-width: 916px) 100vw, 916px" /></a></figure>
<h3 class="wp-block-heading">NextTrip Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTRP#NYSE">NTRP</a>)</h3>
<ul>
<li>On April 7, NextTrip said it has acquired JOURNY TV Channel. The company's stock fell around 65% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/NTRP">low of $1.40</a>.</li>
<li>RSI Value: 24.3</li>
<li>NTRP Price Action: Shares of NextTrip fell 10.3% to close at $2.02 on Tuesday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0430">NTRP shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0430"><img loading="lazy" decoding="async" width="893" height="851" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30041224/image-226.png" alt="" class="wp-image-894297" style="width:522px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30041224/image-226.png 893w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30041224/image-226-300x286.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30041224/image-226-768x732.png 768w" sizes="(max-width: 893px) 100vw, 893px" /></a></figure>
Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and s<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">ee how they compare.</a> 
Read This Next:
<ul>
<li> <a href="https://www.benzinga.com/25/04/45064976/top-3-industrials-stocks-which-could-rescue-your-portfolio-in-q2">Top 3 Industrials Stocks Which Could Rescue Your Portfolio In Q2</a> </li>
</ul>
Photo via Shutterstock

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

ASGN

HCKT

NTRP

Top 3 Tech Stocks That May Surge In April

WIIM

Barclays shares are trading lower. The company reported Q1 financial results.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Wells Fargo analyst Michael Sison upgraded the rating for The Sherwin-Williams Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>) from Equal-Weight to Overweight and raised the price target from $350 to $420. Sherwin-Williams shares closed at $348.13 on Tuesday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Scotiabank analyst Maher Yaghi upgraded the rating for T-Mobile US, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) from Sector Perform to Sector Outperform and raised the price target from $275 to $277.5. T-Mobile shares closed at $241.59 on Tuesday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Paul Lejuez upgraded Warby Parker Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WRBY#NYSE">WRBY</a>) from Sell to Neutral but lowered the price target from $23 to $17. Warby Parker shares closed at $15.80 on Tuesday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Tim Long upgraded the rating for NetApp, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTAP#NASDAQ">NTAP</a>) from Equal-Weight to Overweight and maintained the price target of $115. NetApp shares closed at $87.86 on Tuesday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>DA Davidson analyst Tom White upgraded Airbnb, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) from Neutral to Buy but lowered the price target from $170 to $155. Airbnb shares closed at $125.49 on Tuesday.  <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying NTAP stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="588" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30074314/image-232-1024x588.png" alt="" class="wp-image-894690" style="width:545px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30074314/image-232-1024x588.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30074314/image-232-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30074314/image-232-768x441.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30074314/image-232.png 1110w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45064976/top-3-industrials-stocks-which-could-rescue-your-portfolio-in-q2">Top 3 Industrials Stocks Which Could Rescue Your Portfolio In Q2</a> </li>
</ul>
Photo via Shutterstock

Upgrades

Analyst Ratings

ABNB

NTAP

TMUS

WRBY

This NetApp Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

GSK shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY25 adjusted EPS guidance. Also, the company raised its FY25 sales guidance above estimates.

Wells Fargo analyst Ike Boruchow upgrades VF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VFC#NYSE">VFC</a>) from Underweight to Equal-Weight and lowers the price target from $18 to $12.

Price Target

Wells Fargo Upgrades VF to Equal-Weight, Lowers Price Target to $12

Eric Trump, executive vice president of the Trump Organization and the younger son of President Donald Trump, criticized the current financial system as outdated and inefficient, suggesting that cryptocurrency offers a faster and more cost-effective alternative. 
What Happened: Speaking this week in Dubai, he warned that traditional banks could become obsolete within the next decade if they fail to adapt.
In a thorough critique delivered during his visit to the UAE, which is an emerging hub for digital currencies, Trump called SWIFT "an absolute disaster." 
He said, "there's nothing that can be done on blockchain that can't be done better than the way that the current financial institutions are working," in a conversation <a href="https://www.cnbc.com/2025/04/30/eric-trump-if-banks-dont-watch-whats-coming-theyll-be-extinct-in-ten-years-.html">with</a> CNBC.
"The modern financial system is broken, it's slow, it's expensive," he said. "If the banks don't watch what's coming, they're going to be extinct in 10 years." He argued that decentralized finance allows for private, low-cost transactions and said that the U.S. banking system "favors the ultra-wealthy" and is politically weaponized.
To establish his point about the increasing irrelevance of banks, Trump said: "You can open up a DeFi app right now, you can open up any cryptocurrency app, and you can send money, wallet to wallet, instantaneously, without the expense, without the variability" of banks.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Eric Trump on cryptocurrency: Traditional banks risk going extinct" width="500" height="281" src="https://www.youtube.com/embed/cLnNedcVgcU?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
See Also: <a href="https://www.benzinga.com/markets/equities/25/04/45090925/trumps-call-to-jeff-bezos-over-amazons-tariff-display-plans-draws-criticism-from-peter-schiff-this-is-the-type-of-stuff-you-might-expect-to-see-in-china">Trump&#8217;s Call To Jeff Bezos Over Amazon&#8217;s Tariff Display Earns Peter Schiff&#8217;s Ire: &#8216;Type Of Stuff You Might Expect To See In China&#8217;</a>
Why It Matters: Trump's remarks come at a time when major banks like <a href="https://www.jpmorgan.com/kinexys/index">JP Morgan</a> are creating blockchain platforms and crypto services to keep up with the rapid scale of digital transformation. His comments also coincide with increasing regulatory scrutiny of crypto markets after notable episodes of volatility and collapses.
Meanwhile, the Trump administration has fashioned itself as a <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43836911/trump-reiterates-resolve-to-make-us-the-crypto-capital-critic-labels-idea-of-bitcoin-reserve-legislation-absurd">champion of digital currencies</a>, and the Trump family is entangled with initiatives such as the <a href="https://www.benzinga.com/news/legal/25/04/45077156/trump-affiliated-world-liberty-financial-defies-ethics-concerns-raises-550-million">World Liberty Financial</a> and American Bitcoin.
Eric Trump's comments come just ahead of his father's scheduled trip to the Gulf from May 13 to 16, with stops in the UAE, Saudi Arabia, and Qatar. The visit will mark the first time a U.S. president has visited the Emirati sheikhdom since George W. Bush in 2008.
Trump, dubbed the &#8220;crypto president,&#8221; recently completed his first 100. While he delivered on his campaign promise to establish a national <a href="https://www.benzinga.com/25/03/44183572/trump-establishes-strategic-bitcoin-reserve-funded-by-forfeited-assets-i-made-the-promise">Bitcoin Strategic Reserve</a>, funded with coins seized through asset forfeiture, the move hasn&#8217;t put a stop to Bitcoin's slide. The cryptocurrency, which hit an all-time high of $109,000 before Trump's inauguration, has since <a href="https://www.benzinga.com/25/04/45092876/bitcoin-sinks-13-in-trumps-first-100-days-but-do-you-remember-how-the-apex-crypto-fared-during-bidens-presidency">fallen more than 13%. </a>
Analysts attribute the decline to increasing economic turmoil catalyzed by Trump's aggressive tariff policies. Despite a brief rebound from a low of $76,000, Bitcoin remains far below its peak. 
Read Next: <a href="https://www.benzinga.com/news/earnings/25/04/45089879/paypal-says-buy-now-pay-later-users-spend-33-more-make-17-more-transactions-pushes-for-global-rollout" target="_blank" rel="noreferrer noopener">PayPal Says ‘Buy Now, Pay Later' Users Spend 33% More, Make 17% More Transactions—Pushes For Global Rollout</a>
Image Via Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

General

Eric Trump Warns Banks Could Be 'Extinct In 10 Years' If They 'Don't Watch What's Coming,' Touting Blockchain As 'Better' Alternative

Wells Fargo analyst Ike Boruchow downgrades Victoria's Secret (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSCO#NYSE">VSCO</a>) from Equal-Weight to Underweight and lowers the price target from $25 to $12.

Downgrades

VSCO

Wells Fargo Downgrades Victoria's Secret to Underweight, Lowers Price Target to $12

<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/30105104/bedzinga-1-1024x576.jpg" alt="" class="wp-image-11905" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/30105104/bedzinga-1-1024x576.jpg 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/30105104/bedzinga-1-300x169.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/30105104/bedzinga-1-768x432.jpg 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/30105104/bedzinga-1.jpg 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
The world of crypto trading is undergoing a seismic transformation. What was once a volatile, sentiment-driven market is increasingly governed by machine learning models, sentiment analytics, and AI-optimized strategies. In 2025, the future of crypto isn't just decentralized it's automated. &nbsp;
Auto Trading bots have existed in traditional equity markets for many years, but AI has given them a new edge.
Institutional Traders Are All In on AI
Wall Street and other financial centers are not just watching from the sidelines. Major hedge funds and trading desks are deploying proprietary AI models that parse order book dynamics, social media sentiment, ETF flows, and macroeconomic data in milliseconds. These systems can adapt strategies in real time, optimizing execution without emotional bias.
What makes this shift significant is that it's narrowing the edge that once favored manual traders. The barrier to entry now lies in compute power and access to high-quality data , not just intuition or experience.
Retail Investors Enter the Algorithm Arms Race
Retail platforms are rapidly adapting. Analytics dashboards, and AI-enhanced bots on platforms are democratizing access to algorithmic trading. Users can now backtest strategies, monitor momentum signals, and integrate AI into their portfolios with minimal coding knowledge.
This evolution is creating a smarter retail segment investors who are data-driven, adaptive, and less prone to panic.
Volatility, Liquidity, and the New Normal
With algorithms responding instantly to news, tweets, and regulatory developments, crypto markets in 2025 exhibit micro-volatility which are short bursts of intense movement followed by rapid stabilization. Liquidity providers are increasingly automated as well, meaning spreads tighten faster but whipsaws are more common.
It's a new dynamic where speed and structure outweigh instinct and speculation.
The Future: AI Co-Pilots for Every Investor
Looking ahead, expect more AI "co-pilot" tools and systems that don't just execute trades but explain the reasoning behind them. These tools still require significant back testing to be generally accepted, but natural language interfaces will allow users to ask questions like, "Why did my portfolio shift from ETH to SOL?" and get algorithm-backed answers.
As the crypto ecosystem matures, AI isn't replacing traders—it's augmenting and upgrading them.
<hr class="wp-block-separator has-alpha-channel-opacity" />
Disclosure:
The author does not hold any financial positions in the cryptocurrencies mentioned in this article and has no relevant affiliations with any companies discussed.
Author Bio:
Michael Collins is a veteran financial analyst with three decades of experience in equities, bonds, and macro strategy. He explores how technology is shaping investor behavior at <a href="https://www.cryptoflowzone.com">CryptoFlowZone.com</a>.

Opinion

The AI-Driven Future of Crypto Trading: How Algorithms Are Rewriting Market Strategies

Needham analyst James Ricchiuti maintains CECO Environmental (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CECO#NASDAQ">CECO</a>) with a Buy and raises the price target from $33 to $34.

CECO

Needham Maintains Buy on CECO Environmental, Raises Price Target to $34

COCO

Vita Coco shares are trading higher after the company reported better-than-expected Q1 financial results.

– Reduced Relative Risk of 24-Week Confirmed Disability Worsening Events by 20% in Overall Study Population Compared to Placebo; Even More Prominent 30% Reduction in High Unmet Need Population of Primary Progressive Multiple Sclerosis –
– Showed Consistent Reduction of Disability Worsening in Subpopulations Without Inflammatory Lesions at Baseline in Overall Study Population; Reduced Relative Risk of 24-Week Confirmed Disability Worsening Events in Patients Without Gadolinium-Enhancing Lesions at Baseline by 29% Compared to Placebo –
– Reduced Annualized Rate of Thalamic Brain Volume Loss by 20% Compared to Placebo –
– Confirmed Favorable Safety and Tolerability Observed in Previous Clinical Trials; No New Safety Signals Identified –
– Webcast to be Held Today, April 30, at 8:00 am ET –
NEW YORK, April 30, 2025 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4416494-1&amp;h=1233229441&amp;u=https%3A%2F%2Fimux.com%2F&amp;a=Immunic%2C+Inc.">Immunic, Inc.</a>&nbsp;(NASDAQ:<a href="https://www.benzinga.com/stock/IMUX#NASDAQ">IMUX</a>), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced positive data from its phase 2 CALLIPER trial of nuclear receptor related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), in patients with progressive multiple sclerosis (PMS).

IMUX

Immunic Reports Data From Phase 2 CALLIPER Trial Of Nurr1 Activator, Vidofludimus Calcium, In Patients With Progressive Multiple Sclerosis

2025 Guidance
The Company is maintaining its full year financial guidance for 2025. Specifically, the company anticipates the following:
<ul>
<li>Core sales growth in the range of (0.5%) to +3.5% year-over-year</li>
<li>Adjusted EBITDA of $735 million to $795 million</li>
<li>Adjusted Earnings Per Share of $1.36 to $1.52</li>
<li>Capital Expenditures of approximately $120 million</li>
<li>Free Cash Flow conversion exceeding 90%</li>
</ul>
Share-based metrics in the Company's guidance do not include the effect of any potential share repurchases.

Guidance

GTES

Gates Industrial Affirms FY25 Outlook: Adj EPS Of $1.36-$1.52 Vs $1.42 Estimate; Sales Of $3.43B-$3.56B Vs $3.37B Estimate

Wells Fargo analyst Ike Boruchow upgrades Canada Goose Hldgs (TSX:<a class="ticker" href="https://www.benzinga.com/stock/GOOS#TSX">GOOS</a>) from Underweight to Equal-Weight and maintains the price target from C$11 to C$11.

TSX:GOOS

Wells Fargo Upgrades Canada Goose Hldgs to Equal-Weight, Maintains Price Target to C$11

HC Wainwright &amp; Co. analyst Emily Bodnar reiterates Agenus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>) from Neutral to Neutral.

Reiteration

AGEN

HC Wainwright & Co. Reiterates Neutral on Agenusto Neutral

<ul>
<li>Phase 3 clinical data shows potential predictive biomarkers for treatment response, first identified in Phase 2 study</li>
<li>Biomarkers could be utilized to predict and provide better patient outcomes, including response rates and survival benefits</li>
<li>Positive delayed-type hypersensitivity (DTH) (p = 0.001) and a favorable Neutrophil-to-Lymphocyte Ratio (NLR) (p = 0.02) linked to longer progression-free survival (PFS) in Phase 3 patients</li>
<li>Presence of Circulating Tumor Cells (CTC) after patients' initial Phase 3 treatment supports role as negative prognostic marker (p = 0.04)</li>
<li>Bria-IMT Phase 3 regimen was well-tolerated with a preferred tolerability profile</li>
</ul>
PHILADELPHIA and VANCOUVER, British Columbia, April 30, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCTX#NASDAQ">BCTX</a>, BCTXW, BCTXZ))) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BCT#TSX">BCT</a>) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is presenting clinical data from the pivotal Phase 3 study of its lead product candidate, Bria-IMT&#x2122;, in metastatic breast cancer (BRIA-ABC; <a href="https://www.globenewswire.com/Tracker?data=ybz8DVgm_DDXdomIc09Bnf5ZTBfx0sXWwOqyq2BDn6FG4IWGsMeybTqHsku7QDAwXhaGkSWKrU_L7SMWlA3laHcx91S8kWVPVgciXPJahzyL687kZvcgWSnx1Jv2uvAR">NCT06072612</a>) supporting the use of specific biomarkers to predict patients' clinical response to Bria-IMT treatments.

BCTX

TSX:BCT

Briacell Presents Clinical Data From Pivotal Phase 3 Study Of Bria-IMT, In Metastatic Breast Cancer Supporting Use Of Specific Biomarkers To Predict Patients' Clinical Response To Bria-IMT Treatments

First National (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FXNC#NASDAQ">FXNC</a>) reported quarterly earnings of $0.35 per share which missed the analyst consensus estimate of $0.54 by 35.19 percent. This is a 31.37 percent decrease over earnings of $0.51 per share from the same period last year. The company reported quarterly sales of $21.06 million which missed the analyst consensus estimate of $22.00 million by 4.26 percent. This is a 41.38 percent increase over sales of $14.90 million the same period last year.

Earnings

Earnings Misses

FXNC

First National Q1 Adj. EPS $0.35 Misses $0.54 Estimate, Sales $21.06M Miss $22.00M Estimate

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Nuvectis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCT#NASDAQ">NVCT</a>) with a Buy and raises the price target from $11 to $15.

NVCT

HC Wainwright & Co. Reiterates Buy on Nuvectis Pharma, Raises Price Target to $15

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Piper Sandler raised Visa Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) price target from $383 to $384. Piper Sandler analyst Arvind Ramnani maintained an Overweight rating. Visa shares closed at $341.52 on Tuesday. See how other analysts <a href="https://www.benzinga.com/quote/V/analyst-ratings">view this stock</a>.</li>
<li>TD Securities cut the price target for Starbucks Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) from $102 to $90. TD Securities analyst Agnes Lim maintained a Buy rating. Starbucks shares closed at $84.85 on Tuesday. See how other analysts <a href="https://www.benzinga.com/quote/SBUX/analyst-ratings">view this stock</a>.</li>
<li>Needham cut AtriCure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) price target from $51 to $44. Needham analyst Mike Matson maintained a Buy rating. AtriCure shares closed at $34.65 on Tuesday. See how other <a href="https://www.benzinga.com/quote/ATRC/analyst-ratings">analysts view this stock</a>.</li>
<li>DA Davidson cut the price target for Airbnb, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) from $170 to $155. DA Davidson analyst Tom White upgraded the stock from Neutral to Buy. Airbnb shares closed at $125.49 on Tuesday. <a href="https://www.benzinga.com/quote/ABNB/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JP Morgan cut the price target for PACCAR Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCAR#NASDAQ">PCAR</a>) from $105 to $90. JP Morgan analyst Tami Zakaria downgraded the stock from Overweight to Neutral. PACCAR shares closed at $90.29 on Tuesday. <a href="https://www.benzinga.com/quote/PCAR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Leerink Partners lowered NeoGenomics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) price target from $25 to $9. Leerink Partners analyst Puneet Souda downgraded the stock from Outperform to Market Perform. NeoGenomics shares settled at $6.58 on Tuesday. <a href="https://www.benzinga.com/quote/NEO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Leerink Partners cut Quanterix Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QTRX#NASDAQ">QTRX</a>) price target from $12 to $8. Leerink Partners analyst Puneet Souda downgraded the stock from Outperform to Market Perform. Quanterix shares closed at $6.05 on Tuesday. <a href="https://www.benzinga.com/quote/QTRX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co. cut Zynex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYXI#NASDAQ">ZYXI</a>) price target from $15 to $8. HC Wainwright &amp; Co. analyst Yi Chen maintained a Buy rating. Zynex shares closed at $2.23 on Tuesday.  <a href="https://www.benzinga.com/quote/ZYXI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup lowered the price target for Warby Parker Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WRBY#NYSE">WRBY</a>) from $23 to $19. Citigroup analyst Paul Lejuez upgraded the stock from Sell to Neutral. Warby Parker shares settled at $15.80 on Tuesday. <a href="https://www.benzinga.com/quote/WRBY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Scotiabank increased T-Mobile US, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) price target from $275 to $277.5. Scotiabank analyst Maher Yaghi upgraded the stock from Sector Perform to Sector Outperform. T-Mobile US shares closed at $241.59 on Tuesday. <a href="https://www.benzinga.com/quote/TMUS/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying Visa stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="593" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30073519/image-231-1024x593.png" alt="" class="wp-image-894667" style="width:532px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30073519/image-231-1024x593.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30073519/image-231-300x174.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30073519/image-231-768x444.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30073519/image-231.png 1106w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45064976/top-3-industrials-stocks-which-could-rescue-your-portfolio-in-q2">Top 3 Industrials Stocks Which Could Rescue Your Portfolio In Q2</a> </li>
</ul>
Photo via Shutterstock

ATRC

PCAR

QTRX

SBUX

ZYXI

Visa To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Wednesday

Wells Fargo analyst Ike Boruchow downgrades Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) from Overweight to Equal-Weight and lowers the price target from $75 to $55.

Wells Fargo Downgrades Nike to Equal-Weight, Lowers Price Target to $55

Context Therapeutics Inc. ("Context" or "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTX#NASDAQ">CNTX</a>), a clinical-stage biopharmaceutical company advancing T cell engaging ("TCE") bispecific antibodies for solid tumors, today announced preclinical and translational data regarding the Company's clinical asset, CT-95, a mesothelin x CD3 TCE was presented at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25-30, 2025 in Chicago, IL.&nbsp;

CNTX

Context Therapeutics Presents New Preclinical Data for Solid Tumor Therapy at Major Cancer Conference

Press Releases

Evolv Technology Announces Receipt of Extension from Nasdaq Stock Market

Evolv Technology Announces the Appointment of Richard Shapiro as a New Independent Director

Evolv Announces Official Partnership with Sports Illustrated Stadium and New York Red Bulls

Evolv Technology Deployed Ballpark-Wide at T-Mobile Park for Seattle Mariners 2025 Opening Day

Evolv Technology Announces that 92% of Customers1 Eligible to End Contracts Elect to Stay with Evolv

San Francisco Giants Deploy Latest Evolv Express® Gen2 Systems for 2025 Season

Partnership with Cosm Reinforces Evolv Technology's Sports Industry Position as Innovation Leader

Evolv Receives Expected Nasdaq Delinquency Notification

Evolv Technology Appoints Chris Kutsor as Chief Financial Officer

Evolv Technology Completes Restatement of Previously Issued Financial Statements and Reports Third Quarter, Fourth Quarter and Full Year 2024 Financial Results

Comments

Evolv Technologies

ニュース

パートナーシップ

ベンジンガ・グローバル